IBRX icon

ImmunityBio

126 hedge funds and large institutions have $196M invested in ImmunityBio in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 26 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more capital invested

Capital invested by funds: $ → $

more ownership

Funds ownership:

less funds holding

Funds holding:

19% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $3.79M

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

Holders
126
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$3.06M
Puts
$3.79M
Net Calls
Net Calls Change

Top Buyers

1 +$23.8M
2 +$2.77M
3 +$1.99M
4
Citigroup
Citigroup
New York
+$1.78M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.73M
Name Holding Trade Value Shares
Change
Change in
Stake
76
$117K
77
$112K
78
$111K
79
$103K
80
$96K
81
$94K
82
$93K
83
$92K
84
$78K
85
$72K
86
$70.1K
87
$70K
88
$68K
89
$63K
90
$62K
91
$61K
92
$53K
93
$49.7K
94
$49K
95
$40K
96
$37K
97
$32K
98
$27K
99
$26K
100
$24.6K